GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Cyclically Adjusted Revenue per Share

CytomX Therapeutics (STU:6C1) Cyclically Adjusted Revenue per Share : €1.15 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CytomX Therapeutics's adjusted revenue per share for the three months ended in Mar. 2025 was €0.540. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.15 for the trailing ten years ended in Mar. 2025.

During the past 12 months, CytomX Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-20), CytomX Therapeutics's current stock price is €1.707. CytomX Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €1.15. CytomX Therapeutics's Cyclically Adjusted PS Ratio of today is 1.48.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CytomX Therapeutics was 3.85. The lowest was 0.35. And the median was 0.98.


CytomX Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for CytomX Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Cyclically Adjusted Revenue per Share Chart

CytomX Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.19

CytomX Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.04 1.06 1.19 1.15

Competitive Comparison of CytomX Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

CytomX Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.54/134.9266*134.9266
=0.540

Current CPI (Mar. 2025) = 134.9266.

CytomX Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.052 100.684 0.070
201509 0.049 100.392 0.066
201512 0.051 99.792 0.069
201603 0.055 100.470 0.074
201606 0.076 101.688 0.101
201609 0.085 101.861 0.113
201612 0.163 101.863 0.216
201703 0.298 102.862 0.391
201706 0.212 103.349 0.277
201709 0.548 104.136 0.710
201712 0.596 104.011 0.773
201803 0.298 105.290 0.382
201806 0.469 106.317 0.595
201809 0.244 106.507 0.309
201812 0.224 105.998 0.285
201903 0.578 107.251 0.727
201906 0.176 108.070 0.220
201909 0.214 108.329 0.267
201912 -0.442 108.420 -0.550
202003 0.954 108.902 1.182
202006 0.320 108.767 0.397
202009 0.327 109.815 0.402
202012 -0.274 109.897 -0.336
202103 0.220 111.754 0.266
202106 0.208 114.631 0.245
202109 0.229 115.734 0.267
202112 -0.170 117.630 -0.195
202203 0.126 121.301 0.140
202206 0.186 125.017 0.201
202209 0.171 125.227 0.184
202212 0.287 125.222 0.309
202303 0.331 127.348 0.351
202306 0.343 128.729 0.360
202309 0.305 129.860 0.317
202312 0.299 129.419 0.312
202403 0.462 131.776 0.473
202406 0.275 132.554 0.280
202409 0.354 133.029 0.359
202412 0.424 133.157 0.430
202503 0.540 134.927 0.540

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


CytomX Therapeutics  (STU:6C1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CytomX Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.707/1.15
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CytomX Therapeutics was 3.85. The lowest was 0.35. And the median was 0.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CytomX Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CytomX Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines